Literature DB >> 17015696

The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells.

Klaus Okkenhaug1, Daniel T Patton, Antonio Bilancio, Fabien Garçon, Wendy C Rowan, Bart Vanhaesebroeck.   

Abstract

The role of PI3K in T cell activation and costimulation has been controversial. We previously reported that a kinase-inactivating mutation (D910A) in the p110delta isoform of PI3K results in normal T cell development, but impaired TCR-stimulated cell proliferation in vitro. This proliferative defect can be overcome by providing CD28 costimulation, which raises the question as to whether p110delta activity plays a role in T cell activation in vivo, which occurs primarily in the context of costimulation. In this study, we show that the PI3K signaling pathway in CD28-costimulated p110delta D910A/D910A T cells is impaired, but that ERK phosphorylation and NF-kappaB nuclear translocation are unaffected. Under in vitro conditions of physiological Ag presentation and costimulation, p110delta D910A/D910A T cells showed normal survival, but underwent fewer divisions. Differentiation along the Th1 and Th2 lineages was impaired in p110delta D910A/D910A T cells and could not be rescued by exogenous cytokines in vitro. Adoptive transfer and immunization experiments in mice revealed that clonal expansion and differentiation in response to Ag and physiological costimulation were also compromised. Thus, p110delta contributes significantly to Th cell expansion and differentiation in vitro and in vivo, also in the context of CD28 costimulation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015696     DOI: 10.4049/jimmunol.177.8.5122

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

1.  Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).

Authors:  Yenny Y Acosta; Maria Paz Zafra; Gloria Ojeda; Ilaria Seren Bernardone; Umberto Dianzani; Pilar Portolés; Jose M Rojo
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

Review 2.  Phosphoinositide 3-kinase signalling in lung disease: leucocytes and beyond.

Authors:  David A Medina-Tato; Stephen G Ward; Malcolm L Watson
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

3.  T cell receptor-induced phosphoinositide-3-kinase p110delta activity is required for T cell localization to antigenic tissue in mice.

Authors:  Sarah J Jarmin; Rachel David; Liang Ma; Jan-Guo Chai; Hamlata Dewchand; Aya Takesono; Anne J Ridley; Klaus Okkenhaug; Federica M Marelli-Berg
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

4.  The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites.

Authors:  Molly S Thomas; Jason S Mitchell; Christopher C DeNucci; Amanda L Martin; Yoji Shimizu
Journal:  J Leukoc Biol       Date:  2008-06-03       Impact factor: 4.962

Review 5.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

6.  Targeting the class IA PI3K isoforms p110α/δ attenuates heart allograft rejection in mice by suppressing the CD4+ T lymphocyte response.

Authors:  Chuanlei Yang; Xing Chen; Zhanjie Wei; Jie Xiao; Weiqiang Chen; Yuqiang Shang; Jinping Liu
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

7.  Selective expansion of memory CD4(+) T cells by mitogenic human CD28 generates inflammatory cytokines and regulatory T cells.

Authors:  Manisha Singh; Sreemanti Basu; Christina Camell; Jacob Couturier; Rodolfo J Nudelman; Miguel A Medina; John R Rodgers; Dorothy E Lewis
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

8.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

9.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.

Authors:  Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug
Journal:  Blood       Date:  2010-01-15       Impact factor: 22.113

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.